An admission C-reactive protein-to-albumin ratio cutoff of 6.7 predicted three-month mortality in acute HFrEF with a sensitivity of 75.8%, specificity of 62.5%, and an AUC of 0.713.
Cohort
No
Does the admission C-reactive protein-to-albumin ratio (CAR) predict three-month mortality in patients hospitalized with acute HFrEF?
The C-reactive protein-to-albumin ratio at admission is a practical, low-cost biomarker that independently predicts short-term mortality in patients with acute HFrEF.
Background Inflammation and nutritional status play important roles in the progression and prognosis of heart failure with reduced ejection fraction (HFrEF). The C-reactive protein-to-albumin ratio (CAR) has recently emerged as a potential prognostic biomarker integrating both inflammatory and nutritional pathways. This study evaluated the prognostic significance of admission CAR for predicting three-month mortality in patients hospitalized with acute HFrEF. Methods A prospective single-center study was conducted among patients admitted with acute HFrEF. CAR was calculated at hospital admission using serum C-reactive protein and albumin levels. Demographic and clinical variables were analyzed, and multivariable regression was performed to determine the independent prognostic value of CAR. Receiver operating characteristic (ROC) curve analysis was used to evaluate predictive performance and determine the optimal cutoff value for mortality prediction. Results Admission CAR values were significantly higher in patients who died during the three-month follow-up period. After adjustment for demographic and clinical confounders, CAR remained an independent predictor of short-term mortality. Compared with CRP and albumin assessed individually, CAR demonstrated superior prognostic performance. The optimal CAR cutoff value for predicting three-month mortality was 6.7, with a sensitivity of 75.8% and specificity of 62.5%. The area under the ROC curve was 0.713, indicating moderate discriminative ability. The prognostic significance of CAR remained evident despite the high prevalence of diabetes mellitus within the study population. Conclusion Admission CAR is a reliable and independent predictor of three-month mortality in acute HFrEF. Owing to its low cost, wide availability, and ease of calculation, CAR may serve as a practical bedside biomarker for early risk stratification and management optimization in high-risk patients.
Golzardi等人（Sat,）在急性心力衰竭伴有射血分数降低（HFrEF）中进行了队列研究。入院时评估C反应蛋白与白蛋白比率（CAR）对三个月死亡率的影响。入院时C反应蛋白与白蛋白比率的临界值为6.7，预测急性HFrEF的三个月死亡率，灵敏度为75.8%、特异性为62.5%，AUC为0.713。
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: